BioAtla, Inc.
BCABBioAtla is a clinical-stage biopharmaceutical company focused on developing a novel class of highly specific antibody-based therapeutics for solid tumor cancers.
Table of contents
Earnings
Next report
Aug 6, 2026 (In 1 week)Competitors
By market cap
By revenue growth
Profile
BioAtla is a clinical-stage biopharmaceutical company focused on developing a novel class of highly specific antibody-based therapeutics for solid tumor cancers. The company utilizes its proprietary Conditionally Active Biologics (CAB) technology to design antibodies that selectively bind to targets within the acidic tumor microenvironment while remaining inactive in healthy tissue. This approach aims to maximize therapeutic potency while significantly reducing on-target, off-tumor toxicities.
BioAtla is a pioneer in conditionally active biologics, leveraging a proprietary protein discovery platform to target widely validated antigens that were previously untreatable due to systemic toxicity.
Questions, answered.
- What is BioAtla, Inc.'s market cap?
- BioAtla, Inc. (BCAB) has a market capitalization of $5.6M and trades on NASDAQ.
- Who are BioAtla, Inc.'s competitors?
- BioAtla, Inc.'s key competitors include Merck & Co., Cabaletta Bio, Inc. Common Stock, Allogene Therapeutics, Inc. Common Stock, and others. These companies compete in similar markets and product categories.
- Who does BioAtla, Inc. partner with?
- BioAtla, Inc.'s notable partners include Bristol-Myers Squibb, Context Therapeutics Inc., BeOne Medicines, Ltd., and others.
- What subsidiaries does BioAtla, Inc. have?
- BioAtla, Inc.'s subsidiaries include BA 3021 SPV LLC.
- Where is BioAtla, Inc. headquartered?
- BioAtla, Inc. is headquartered in United States of America and employs approximately 65 people. It has been publicly traded since 2020.